



10 Collyer Quay
#10-01 Ocean Financial Centre
Singapore 049315
Registration No: 201835258H

UpHealth Group highlights strong patient growth at annual general meeting

Singapore, 8 May 2026 – UpHealth Group Limited (formerly known as Don Agro International Limited) (the "Company" or "UpHealth"), and its subsidiaries (the "Group"), held its Annual General Meeting ("AGM"), marking the first AGM since the completion of its transformation from an agricultural company into a fully operational healthcare business.

The key highlight of the AGM was the substantial operational momentum demonstrated by the healthcare assets the Group acquired, which together treated more than 54,000 patients during 2025:

- Oncology clinic network Euroonco served 13,705 patients, an increase of approximately 24% from 11,019 patients in FY2024.
- Uni Clinic, which came under the Group's management at the beginning of FY2025, contributed an additional 40,329 patients.

The combined patient volume of more than 54,000 represented a several-fold increase compared to the standalone Euroonco network in the prior year, confirming that the Board's decision to enter into the healthcare industry was the right one.

Transformation Complete – No Longer a Cash Company

The Group entered FY2025 as Don Agro International Limited, following the disposal of its agricultural business and a period operating as a cash company.

The acquisition of the healthcare business was fully completed in February 2026. Following this completion, UpHealth now owns and operates two core healthcare assets: Euroonco, a network of expert oncology clinics across three major cities in Russia with inpatient capacity exceeding 64 beds, and Uni Medica, a 7,000 square meter multifunctional medical facility with 27 inpatient beds and 70 fully equipped outpatient rooms. The Group plans to expand Uni Medica's inpatient capacity to up to 72 inpatient beds over time and integrate it with Euroonco to support the treatment of oncology patients.

While the healthcare business had not yet been consolidated into the Group's FY2025 financial results, its operating performance clearly demonstrates the substance and scale of the business the Board chose to acquire.

"The patient growth numbers speak for themselves. Euroonco clinics grew 24% year-on-year, and the addition of Uni Clinic added more than 40,000 patients in a single year. This growth stands in stark contrast to the agricultural market we exited. Global grain prices have continued their downward trend in 2025, with

PRESS RELEASE

the Food and Agriculture Organization forecasting another year of broad-based commodity price declines, with prices projected to remain under pressure in 2026 and 2027. This proves that our decision to move from agriculture into healthcare was the right one.

According to the World Health Organization's International Agency for Research on Cancer (IARC), there were nearly 20 million new cancer cases globally in 2025¹. By 2050, improved detection rates and aging populations are projected to bring over 35 million new confirmed diagnoses annually². This growing need for specialised oncology care validates our plans — not only to expand treatment capacity within our existing clinics, but to grow our asset base and geographical presence across other countries and regions”, commented **Mr. Evgeny Tugolukov, Executive Chairman of UpHealth Group Limited**.

Looking Ahead: International Expansion

Beyond its established operations, the Board continues to review opportunities to expand the Group's presence in selected international markets, including Southeast Asia, Central Asia, and the Middle East, through acquisitions and partnerships with leading healthcare providers.

The global healthcare services market reached US\$8.53 trillion in 2024 and is expected to grow to US\$10.75 trillion in 2029, representing a compound annual growth rate of 4.7%³. The Group believes this structural demand makes healthcare a resilient and scalable business across different geographies.

This press release has been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (“Exchange”) and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg

¹ <https://www.forbes.com/sites/omerawan/2026/02/01/world-cancer-day-2026-data-disparities-and-the-future/>

² <https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services>

³ Information obtained from The Business Research Company, <https://www.thebusinessresearchcompany.com/report/healthcare-service-global-market-report>